CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim
Cancer Research and Treatment. 2023;55(1):325-333.   Published online 2022 April 22    DOI: https://doi.org/10.4143/crt.2022.008

Excel Download

Outcomes of salvage chemotherapy and autologous transplantation for large cell transformation of follicular lymphoma—A comparison of outcomes with relapsed/refractory diffuse large B cell lymphoma
Biology of Blood and Marrow Transplantation. 2006;12(2):120   Crossref logo
Link1 Link2

Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study
Clinical Lymphoma Myeloma and Leukemia. 2016;16:S101   Crossref logo
Link1 Link2

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Cancer Research and Treatment. 2023;55(1):325-333   Crossref logo
Link1 Link2 Link3

Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies
Clinical Lymphoma Myeloma and Leukemia. 2022;22(6):373-381   Crossref logo
Link1 Link2

Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies
Clinical Lymphoma Myeloma and Leukemia. 2020;20(10):661-667   Crossref logo
Link1 Link2

TREATMENT OF RELAPSED, REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Hematology, Transfusion and Cell Therapy. 2021;43:S4   Crossref logo
Link1 Link2

A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma
The Korean Journal of Hematology. 2011;46(1):57   Crossref logo
Link1 Link2 Link3

CAR-T cell therapies cost effective in diffuse large B-cell lymphoma?
PharmacoEconomics & Outcomes News. 2019;830(1):7-7   Crossref logo
Link1 Link2 Link3

NICE recommends Kymriah for diffuse large B-cell lymphoma
PharmacoEconomics & Outcomes News. 2019;821(1):34-34   Crossref logo
Link1 Link2 Link3

Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy. Cancer. 2017;123:4411-4418.
Cancer. 2017;124(4):867-867   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.